Mark Schmidt to Treatment Outcome
This is a "connection" page, showing publications Mark Schmidt has written about Treatment Outcome.
Connection Strength
0.161
-
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.
Score: 0.044
-
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 10; 26(10):1210-1217.
Score: 0.032
-
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019 03; 49(5):599-608.
Score: 0.031
-
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. Gastroenterology. 2018 02; 154(3):754-758.
Score: 0.029
-
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. Clin Gastroenterol Hepatol. 2016 07; 14(7):1044-1055.e3.
Score: 0.025